Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough moss-based platform, announced today the appointment of Dr Martin Bauer, MD, as new Chief Medical Officer. His appointment reflects the growing maturity of Eleva’s proprietary pipeline, which includes Eleva’s Factor H (CPV-104) program, a novel complement regulator with therapeutic potential in several indications, and aGal (RPV-001), a best-in-class approach to treat Fabry disease.
Martin Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility. His roles include senior and leadership positions at Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. He is board-certified in Anesthesiology, Rescue Medicine, and Medical Informatics, and has over 10 years of experience working in academic hospitals. Martin Bauer earned his MD from Julius-Maximilians University of Würzburg, Germany.
“With the clinical trial start for our second fully owned drug development program on the horizon, we have decided to appoint an experienced Chief Medical Officer orchestrating all of these activities,” commented Björn Cochlovius Ph.D., Chief Executive Officer of Eleva.“Martin’s deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organisation.”
Commenting on his appointment, Martin Bauer added: “I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programs and potentially new indications being explored. Our Factor H program in particular has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care.”
